Acrux signs second distribution agreement with CSL
Tuesday, 30 November, 2004
Acrux (ASX: ACR) has signed a second distribution agreement with CSL (ASX: CSL), giving CSL the rights to distribute Acrux's Fentanyl MDTS treatment for severe pain.
The product, which is undergoing Phase I clinical development, will be distributed by CSL Pharmaceuticals in Australia and New Zealand. Acrux will receive both an upfront payment plus royalties on net sales.
Earlier this year, CSL agreed to distribute Acrux's testosterone MDTS treatment for low testosterone levels and sexual dysfunction in women.
New drug to prevent migraine claimed to work straight away
People taking atogepant showed improvement on assessments of how much migraine impaired their...
Your stool can reveal your risk of cardiovascular disease
Certain faecal proteins have been linked to deadly cardiovascular conditions. A connection...
Targeting the stress system reduces Parkinson's tremors
The commonly used Parkinson's drug levodopa usually helps with tremors, but it tends to be...
